Protalix reports 2023 net income $8.3M vs loss; Elfabrio approvals, $20M milestone

Protalix BioTherapeutics, Inc.

Revenue from goods $40.4M (+60% YoY); license/R&D services $25.1M (+13%).
Net income $8.3M ($0.12 diluted EPS) vs net loss $14.9M in 2022.
Cash $44.6M at year-end; Elfabrio approved in US, EU, UK, Switzerland, Israel.
$20M milestone from Chiesi triggered by FDA approval; $17.5M Elfabrio sales post-approval.
PRX-115 Phase I fully enrolled; results expected Q2 2024. New chairman appointed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2023 and provided a business update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-003160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.